全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 254750-02-2 |
|---|---|---|---|
| 分子式 | C26H27F4N3O7 | 纯度 | 99.00 % |
| 分子量 | 569.50 | 货号 | abs816139 |
| 规格 | 5mg | 供货周期 | 现货 |
| 主要用途 | is a potent irreversible pan-caspase inh | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Emricasan 254750-02-2
| 产品描述 | |
| 描述 | Emricasan is a potent irreversible pan-caspase inhibitor. |
| 纯度 | 99.00 % |
| 储存/保存方法 | store at -20℃ for one year（Powder）； in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months. |
| 基本信息 | |
| 可溶性/溶解性 | 体外: DMSO 100mg/mL(175.59mM) Ethanol 100mg/mL(175.59mM) Water <1mg/mL |
| 生物活性 | |
| 靶点 | caspase |
| In vitro(体外研究) | Emricasan, also called IDN-6556 or PF-03491390, is an inhibitor of activated caspases, and it has sub- to nanomolar activity in vitro. Emricasan shows neuroprotective activity for hNPCs but does not suppress ZIKV replication. |
| In vivo(体内研究) | Emricasan decreases liver injury but not metabolic derangement in NASH. It also ameliorates inflammation. In the murine NASH model, stellate cell activation and hepatic fibrogenesis are attenuated by administration of the pan-caspase inhibitor Emricasan. Emricasan is currently being evaluated in phase 2 clinical trials for the reduction of hepatic injury and liver fibrosis caused by chronic HCV infection. |
| 参考文献 | |
| 参考文献 | [1] Barreyro FJ, et al. Liver Int. 2015, 35(3):953-66. [2] Xu M, et al. Nat Med. 2016, [Epub ahead of print]. |
| 研究领域 | |
| 研究领域 | Apoptosis Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：